Browsing Tag
AZN
2 posts
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
AstraZeneca (LSE: AZN) goes big on U.S. supply chain with latest $2bn manufacturing push
AstraZeneca invests $2B in Maryland to expand biologics and rare disease drug manufacturing. Find out what this means for U.S. jobs and the pharma supply chain.